68Ga-FAPI PET/CT对原发性及复发性胰腺导管腺癌治疗管理的影响
该回顾性研究纳入19例胰腺导管腺癌(PDAC)患者(7例初诊,12例进展/复发),比较68Ga-FAPI PET/CT与增强CT的TNM分期及治疗管理变化。68Ga-FAPI PET/CT使10/19例分期改变,7例治疗管理调整,复发病例多数被上调分期;但注射后1小时静态显像难以鉴别胰腺炎,多时间点显像显示摄取动力学趋势差异。
要点
- 68Ga-FAPI PET/CT较增强CT改变10/19例PDAC患者TNM分期。
- 12例复发/进展患者中8例上调分期,1例下调,3例无变化。
- 7例患者因68Ga-FAPI PET/CT结果调整肿瘤治疗管理。
核心结论
- 68Ga-FAPI PET/CT较标准影像使半数PDAC患者重新分期,复发病例多数分期上调,并导致7例治疗管理改变。
- 68Ga-FAPI PET/CT的临床价值需进一步研究。
研究设计与样本
- 回顾性研究,纳入19例PDAC患者(7例初诊,12例进展/复发)。
- 所有患者先行增强CT进行TNM分期,再行68Ga-FAPI PET/CT,注射150-250 MBq后60分钟采集,6例加采10或180分钟。
- 比较68Ga-FAPI PET/CT与增强CT的TNM分期及肿瘤治疗管理变化。
主要发现
- 68Ga-FAPI PET/CT较增强CT使10/19例患者TNM分期改变。
- 12例复发/进展患者中8例上调分期、1例下调、3例无变化;7例初诊患者中1例上调、6例无变化。
- 7例患者发生肿瘤治疗管理改变。
- 多数病例PDAC病灶在注射后1小时68Ga-FAPI摄取明显升高;1小时静态显像难以鉴别胰腺炎,多时间点显像显示PDAC与胰腺炎摄取动力学有差异趋势。
临床怎么用
- 对PDAC患者(尤其复发/进展者),68Ga-FAPI PET/CT可提供优于增强CT的分期信息并影响治疗决策。
- 注射后1小时静态显像鉴别胰腺炎困难,多时间点显像可能有助于鉴别。
局限性
- 回顾性研究,样本量小(19例)。
- 68Ga-FAPI PET/CT的临床价值需进一步研究验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Pancreatic ductal carcinoma (PDAC) is a highly lethal cancer, and early detection and accurate staging are critical to prolonging survival. PDAC typically has a prominent stroma including cancer-associated fibroblasts that express fibroblast activation protein (FAP). FAP is a new target molecule for PET imaging of various tumors. In this retrospective study, we describe the clinical impact of PET/CT imaging using 68Ga-labeled FAP-inhibitors (68Ga-FAPI PET/CT) in 19 patients with PDAC (7 primary, 12 progressive/recurrent). Methods: All patients underwent contrast-enhanced CT (ceCT) for TNM staging before 68Ga-FAPI PET/CT imaging. PET scans were acquired 60 min after administration of 150-250 MBq of 68Ga-labeled FAP-specific tracers. To characterize 68Ga-FAPI uptake over time, additional scans after 10 or 180 min were acquired in 6 patients. SUVmax and SUVmean values of PDAC manifestations and healthy organs were analyzed. The tumor burden according to 68Ga-FAPI PET/CT was compared with TNM staging based on ceCT and changes in oncologic management were recorded. Results: Compared with ceCT, 68Ga-FAPI PET/CT results led to changes in TNM staging in 10 of 19 patients. Eight of 12 patients with recurrent/progressive disease were upstaged, 1 was downstaged, and 3 had no change. In newly diagnosed PDAC, 1 of 7 patients was upstaged, and the staging of 6 patients did not change. Changes in oncologic management occurred in 7 patients. Markedly elevated uptake of 68Ga-FAPI in PDAC manifestations after 1 h was seen in most cases. Differentiation from pancreatitis based on static imaging 1 h after injection was challenging. With respect to imaging after multiple time points, PDAC and pancreatitis showed a trend for differential uptake kinetics. Conclusion:68Ga-FAPI PET/CT led to restaging in half of the patients with PDAC and most patients with recurrent disease compared with standard of care imaging. The clinical value of 68Ga-FAPI PET/CT should be further investigated.
引用
- Röhrich M, Naumann P, Giesel FL, et al. Impact of 68Ga-FAPI PET/CT Imaging on the Therapeutic Management of Primary and Recurrent Pancreatic Ductal Adenocarcinomas. J Nucl Med. 2020. PMID: 33097632. doi:10.2967/jnumed.120.253062
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。